DENTSPLY SIRONA Inc. (XRAY) is a publicly traded company in the Healthcare — Medical - Instruments & Supplies industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
DENTSPLY SIRONA Inc. develops, manufactures, and markets dental equipment supported by cloud-enabled solutions, dental products, and healthcare consumable products in urology and enterology worldwide. It operates through four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare.
Is DENTSPLY SIRONA Inc. stock overvalued or undervalued in 2026?
As of November 4, 2026, DENTSPLY SIRONA Inc. (XRAY) trades at $10.65 with no positive earnings over the last twelve months, according to Kaplio. No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: DENTSPLY SIRONA Inc.
Market cap $2B · 52 weeks $8 – $15 (36% below the high) · P/E no earnings · 2027 est. P/E 7.0× · Dividend 1.5% · Next earnings November 5, 2026 · expected EPS $0.30 · Closing price, Nov 4 · accounts published Aug 6.
- Valuation: EV/EBITDA 42.7× (no earnings).
- Business: ROIC 10% (fair).
- Balance sheet: Altman Z 0.9 (fragile).
- Earnings: 4 of 8 (uneven).
Where would it trade at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in pharma: 0 of 3 pass
- R&D / Revenue 4.1%, fails.
- Gross margin 50.0%, fails.
- ROIC 10.0%, fails.
- Net debt / EBITDA n. s., info.
Against its peers (reference peers) — DENTSPLY SIRONA Inc.: P/E —; EV/EBITDA 42.7×; ROIC 10.0%; $2.1B. Envista Holdings Corp (P/E 7.0×; EV/EBITDA 5.8×; ROIC 14.1%; $4.4B), Henry Schein, Inc. (P/E 25.7×; EV/EBITDA 12.3×; ROIC 6.5%; $9.8B), Align Technology, Inc. (P/E 24.0×; EV/EBITDA 14.3×; ROIC 10.3%; $11.7B).
Dividend
tight (only raised recently) · Yield (last 12 months) 1.5% · $0.64 per share in 2025 · 5-year growth +10% a year · Free cash flow coverage 1.6× (last three fiscal years) · With $1,000 invested today you'd collect $15.00 a year ($1.25 a month).
Profitability
| Return on Equity | -39.81% |
| Return on Invested Capital | 10.03% |
| Return on Assets | -10.49% |
| Gross Margin | 49.52% |
| Operating Margin | 11.69% |
| Net Margin | -14.99% |
Financial Health
| Debt / Equity | 1.71 |
| Current Ratio | 1.63 |
| Piotroski F-Score | 5 |
| Altman Z-Score | 0.91 |
Price Performance
| 1 month | +10.80% |
| 3 months | -22.11% |
| Year-to-date | -17.41% |
| 1 year | -25.20% |
| 3 years | -66.95% |
| 5 years | -83.09% |
| 10 years | -84.55% |
Dividend History
Paid in the last 12 months: $0.16 per share in 1 payments.
| Date | Amount |
|---|---|
| December 26, 2025 | $0.16 |
| September 26, 2025 | $0.16 |
| June 27, 2025 | $0.16 |
| March 28, 2025 | $0.16 |
| December 27, 2024 | $0.16 |
| September 27, 2024 | $0.16 |
| June 28, 2024 | $0.16 |
| March 27, 2024 | $0.16 |
| December 28, 2023 | $0.14 |
| September 28, 2023 | $0.14 |
Amounts adjusted for stock splits.
Related companies: ALGN · HSIC · NVST · ISRG · 0R29.L · BDX · 0R19.L · MDLN
Explore sector: Healthcare · Medical - Instruments & Supplies
More sections of XRAY: Financials · Valuation · Estimates · Technical · Ownership
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks